Traders should watch for commercial launch updates and initial prescription uptake by end of 2026. The stock may re-rate as Spero moves from clinical-stage to commercial-stage. Monitor for potential milestone payments from GSK under the license agreement.
Price Chart
Executive Summary
Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated UTIs in adults. The approval is based on the PIVOT-PO Phase III trial showing non-inferiority vs IV imipenem-cilastatin. The drug is expected to be available in the US by end of 2026. This is a major product approval for Spero, a clinical-stage biopharma with a $132M market cap, and validates its partnership with GSK.
Key Facts
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis on June 17, 2026
- First and only oral carbapenem antibiotic approved in the US
- Approval based on PIVOT-PO Phase III trial demonstrating non-inferiority vs IV imipenem-cilastatin (adjusted treatment difference: -1.3%; 95% CI: -7.5%, 4.8%)
- More than 3 million cases of cUTIs treated annually in the US; a third of patients impacted by resistant infections
- Drug anticipated to be available to US patients by end of 2026
- Approval received one day ahead of PDUFA date of June 18, 2026
- Spero is a clinical-stage biopharma with $132M market cap; no current revenue from approved products
Financial Impact
Transformative for Spero as it transitions from clinical-stage to having an FDA-approved product. The cUTI market represents over $6B in annual US healthcare costs. No specific revenue or deal value disclosed.
Risk Factors
- Commercial launch and market adoption may be slower than anticipated
- Spero is still a small-cap with limited commercial infrastructure; relies on GSK for commercialization
- Competitive landscape for oral antibiotics and potential label limitations
- Forward-looking statements about commercial success are subject to risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-277506 |
| Document: d51395d8k.htm | 0001193125-26-277506 |
| Document: 0001193125-26-277506-index-headers.html | 0001193125-26-277506 |
| Document: 0001193125-26-277506-index.html | 0001193125-26-277506 |
| Document: 0001193125-26-277506.txt | 0001193125-26-277506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.20 (−5.75%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.20 (+2.05%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.20 (−3.63%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.20 (−29.71%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.20 (−47.12%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.20 (−44.42%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.20 (−43.36%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.20 (−56.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access